ILMN · Company research
Illumina Inc (ILMN): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
35records availableTechnology
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| How to Find Strong Medical Stocks Slated for Positive Earnings Surprises | The article explains how to identify medical stocks positioned for positive earnings surprises using the Zacks Earnings ESP (Expected Surprise Prediction) filter. It demonstrates that combining positive ESP with a Zacks Rank #3 or better has historically resulted in positive earnings surprises 70% of the time with 28.3% average annual returns. Two medical stocks are highlighted as examples: Illumina with a +9.16% ESP and Buy rating, and Vertex Pharmaceuticals with a +4.98% ESP and Hold rating. | View source ↗ | Zacks Investment Research | Oct 20, 2026 | bullish | 1 | 1 |
| Single Cell Sequencing Market Forecast to 2035: Services, Technologies, End-users, Applications, and Regions | 15% CAGR Drives Drug Discovery and Precision Medicine Growth | The global single cell sequencing market is estimated at USD 1.38 billion and is projected to expand at a 15% CAGR through 2035, driven by advances in genomics, declining sequencing costs, and wider adoption in drug discovery, diagnostics, and precision medicine. North America is expected to account for approximately 50% of the market, with academic institutions representing the largest end-user segment at 60%. Key challenges include data processing requirements, quality management, and workflow costs. | View source ↗ | GlobeNewswire Inc. | Oct 20, 2026 | bullish | 1 | 1 |
| BE, P, ILMN Join S&P 500; LNG Misses Out — Bloom Energy Stock Gains While Cheniere Energy Slips - Stocktwits | BE, P, ILMN Join S&P 500; LNG Misses Out — Bloom Energy Stock Gains While Cheniere Energy Slips Stocktwits | View source ↗ | Stocktwits | Oct 17, 2026 | neutral | 0 | 0.6 |
| Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? | Illumina is positioned to potentially beat earnings estimates in its next quarterly report on October 29, 2026. The company has a strong track record of beating estimates, with an average surprise of 8.01% over the last two quarters. With a positive Earnings ESP of +9.16% and a Zacks Rank #2 (Buy), analysts have recently become bullish on the company's earnings prospects. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million | Saudi Arabia's Non-Invasive Prenatal Testing (NIPT) market is projected to grow from US$52.50 million in 2025 to US$162.16 million by 2034, driven by a 13.35% CAGR. Growth is fueled by advances in next-generation sequencing, rising maternal age, increased healthcare investment, and expanding genetic testing capacity. Key players include Eurofins Scientific, Roche, Invitae, Illumina, Natera, Centogene, and Qiagen, with Riyadh and Jeddah leading regional adoption. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 1 | 1 |
| Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million | Saudi Arabia's Non-Invasive Prenatal Testing (NIPT) market is projected to grow from US$52.50 million in 2025 to US$162.16 million by 2034, driven by a 13.35% CAGR. Growth is fueled by advances in next-generation sequencing, rising maternal age, increased healthcare investment, and expanding genetic testing capacity. Key players include Eurofins Scientific, Roche, Invitae, Illumina, Natera, Centogene, and Qiagen, with Riyadh and Jeddah leading regional adoption. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 1 | 1 |
| Saudi Arabia Non-Invasive Prenatal Testing Market 2026-2034: Executive Report | NGS Adoption and Healthcare Investment Drive 13.35% CAGR Toward US$162.16 Million | Saudi Arabia's Non-Invasive Prenatal Testing (NIPT) market is projected to grow from US$52.50 million in 2025 to US$162.16 million by 2034, driven by a 13.35% CAGR. Growth is fueled by advances in next-generation sequencing, rising maternal age, increased healthcare investment, and expanding genetic testing capacity. Key players include Eurofins Scientific, Roche, Invitae, Illumina, Natera, Centogene, and Qiagen, with Riyadh and Jeddah leading regional adoption. | View source ↗ | GlobeNewswire Inc. | Oct 15, 2026 | bullish | 1 | 1 |
| $100 Invested In Illumina 15 Years Ago Would Be Worth This Much Today - Benzinga | $100 Invested In Illumina 15 Years Ago Would Be Worth This Much Today Benzinga | View source ↗ | Benzinga | Oct 14, 2026 | neutral | 0 | 0.6 |
| Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? | PBE is a smart beta ETF focused on biotechnology and genome companies with $412.99 million in assets. It has delivered strong year-to-date returns of 16.68% and one-year returns of 36.23%, but carries higher risk with a standard deviation of 20.18%. The fund charges a 0.59% expense ratio and holds concentrated positions in healthcare stocks like Natera, Illumina, and Biogen. Cheaper alternatives like XBI and IBB are available for investors seeking lower-cost options. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.5 | 1 |
| Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? | PBE is a smart beta ETF focused on biotechnology and genome companies with $412.99 million in assets. It has delivered strong year-to-date returns of 16.68% and one-year returns of 36.23%, but carries higher risk with a standard deviation of 20.18%. The fund charges a 0.59% expense ratio and holds concentrated positions in healthcare stocks like Natera, Illumina, and Biogen. Cheaper alternatives like XBI and IBB are available for investors seeking lower-cost options. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.5 | 1 |
| Illumina (NasdaqGS:ILMN) Stock Forecast & Analyst Predictions - Simply Wall Street | Illumina (NasdaqGS:ILMN) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 14, 2026 | neutral | 0 | 0.6 |
| Should Invesco S&P MidCap Quality ETF (XMHQ) Be on Your Investing Radar? | The Invesco S&P MidCap Quality ETF (XMHQ) offers broad exposure to mid-cap blend stocks with $5.46 billion in assets and a competitive 0.25% expense ratio. The ETF has returned 11.95% year-to-date and 12.26% over the past year, with heavy allocation to Industrials (29.4%). It holds a Zacks ETF Rank of 2 (Buy), though larger competitors like Vanguard Morningstar Mid-Cap ETF and iShares Core S&P Mid-Cap ETF offer lower expense ratios. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.6 | 1 |
| Should Invesco S&P MidCap Quality ETF (XMHQ) Be on Your Investing Radar? | The Invesco S&P MidCap Quality ETF (XMHQ) offers broad exposure to mid-cap blend stocks with $5.46 billion in assets and a competitive 0.25% expense ratio. The ETF has returned 11.95% year-to-date and 12.26% over the past year, with heavy allocation to Industrials (29.4%). It holds a Zacks ETF Rank of 2 (Buy), though larger competitors like Vanguard Morningstar Mid-Cap ETF and iShares Core S&P Mid-Cap ETF offer lower expense ratios. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.6 | 1 |
| Illumina Inc (ILMN) Stock Up 5.1% but GF Value Says Overvalued -- GF Score: 65/100 - GuruFocus | Illumina Inc (ILMN) Stock Up 5.1% but GF Value Says Overvalued -- GF Score: 65/100 GuruFocus | View source ↗ | GuruFocus | Oct 9, 2026 | neutral | 0 | 0.6 |
| After shares were delivered or withheld for exercise price or tax liability, Illumina (ILMN) CEO holds 107,770 shares. - Stock Titan | After shares were delivered or withheld for exercise price or tax liability, Illumina (ILMN) CEO holds 107,770 shares. Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| With voting power over 15.4M shares, FMR reports a passive stake in Illumina (ILMN). - Stock Titan | With voting power over 15.4M shares, FMR reports a passive stake in Illumina (ILMN). Stock Titan | View source ↗ | Stock Titan | Oct 7, 2026 | neutral | 0 | 0.6 |
| Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation | The global microfluidics market is projected to grow from $21.58 billion in 2025 to $48.04 billion by 2036, with a CAGR of 7.49%. Growth is driven by rising demand for rapid diagnostics, point-of-care testing, genomic analysis, and automated workflows. Microfluidic consumables dominate with 66.7% market share, while Asia-Pacific is expected to register the highest regional growth at 8.72% CAGR. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bullish | 1 | 1 |
| Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation | The global microfluidics market is projected to grow from $21.58 billion in 2025 to $48.04 billion by 2036, with a CAGR of 7.49%. Growth is driven by rising demand for rapid diagnostics, point-of-care testing, genomic analysis, and automated workflows. Microfluidic consumables dominate with 66.7% market share, while Asia-Pacific is expected to register the highest regional growth at 8.72% CAGR. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bullish | 1 | 1 |
| Illumina (ILMN) Shares Skyrocket, What You Need To Know - TradingView | Illumina (ILMN) Shares Skyrocket, What You Need To Know TradingView | View source ↗ | TradingView | Oct 5, 2026 | neutral | 0 | 0.6 |
| Illumina Inc Stock (ILMN) Moved Up by 7.85% on Oct 5: Drivers Behind the Movement - TradingKey | Illumina Inc Stock (ILMN) Moved Up by 7.85% on Oct 5: Drivers Behind the Movement TradingKey | View source ↗ | TradingKey | Oct 5, 2026 | neutral | 0 | 0.6 |
| Illumina (NasdaqGS:ILMN) Stock Price - Simply Wall Street | Illumina (NasdaqGS:ILMN) Stock Price Simply Wall Street | View source ↗ | Simply Wall Street | Oct 5, 2026 | neutral | 0 | 0.6 |
| Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR | The global immunogenomics market is projected to grow from USD 6.32 billion in 2025 to USD 9.82 billion by 2033, expanding at a CAGR of 5.97%. Growth is driven by advancements in next-generation sequencing technologies, increasing demand for personalized medicine, and rising prevalence of immune-related disorders. Key applications include oncology, infectious disease research, vaccine development, and autoimmune disorder studies, with adoption across hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions. | View source ↗ | GlobeNewswire Inc. | Oct 5, 2026 | bullish | 1 | 1 |
| Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight | The global liver cancer diagnostics market is projected to grow from USD 10.5 billion in 2025 to USD 19.8 billion by 2034, driven by rising hepatocellular carcinoma incidence, increasing chronic liver disease prevalence, and advances in diagnostic technologies including liquid biopsy, AI-assisted imaging, and blood-based biomarkers. North America leads the market with 41% share, while Asia-Pacific is expected to be the fastest-growing region. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bullish | 1 | 1 |
| Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight | The global liver cancer diagnostics market is projected to grow from USD 10.5 billion in 2025 to USD 19.8 billion by 2034, driven by rising hepatocellular carcinoma incidence, increasing chronic liver disease prevalence, and advances in diagnostic technologies including liquid biopsy, AI-assisted imaging, and blood-based biomarkers. North America leads the market with 41% share, while Asia-Pacific is expected to be the fastest-growing region. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | bullish | 1 | 1 |
| Illumina (ILMN) Stock May Be Near Fair Value After Raised Guidance - Simply Wall Street | Illumina (ILMN) Stock May Be Near Fair Value After Raised Guidance Simply Wall Street | View source ↗ | Simply Wall Street | Sep 25, 2026 | neutral | 0 | 0.6 |
| Illumina Stock Is Up 133% This Year. Here’s Where It Could Go Further. - TIKR.com | Illumina Stock Is Up 133% This Year. Here’s Where It Could Go Further. TIKR.com | View source ↗ | TIKR.com | Sep 20, 2026 | neutral | 0 | 0.6 |
| ILMN Stock Keeps Climbing. Should You Climb On? - Trefis | ILMN Stock Keeps Climbing. Should You Climb On? Trefis | View source ↗ | Trefis | Sep 8, 2026 | neutral | 0 | 0.6 |
| Illumina slides as investors appear to lock in gains and weigh recent insider sale filings | ILMN Stock News - Quiver Quantitative | Illumina slides as investors appear to lock in gains and weigh recent insider sale filings | ILMN Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 28, 2026 | neutral | 0 | 0.6 |
| Illumina (ILMN) director’s funds unload stock over 3 days - Stock Titan | Illumina (ILMN) director’s funds unload stock over 3 days Stock Titan | View source ↗ | Stock Titan | Aug 27, 2026 | neutral | 0 | 0.6 |
| Illumina Stock Is Up 92% in a Year. Here’s What Analysts Are Saying. - TIKR.com | Illumina Stock Is Up 92% in a Year. Here’s What Analysts Are Saying. TIKR.com | View source ↗ | TIKR.com | Aug 18, 2026 | neutral | 0 | 0.6 |
| Illumina (ILMN) Stock Climbs On Clinical Growth Despite Margin Pressure - Simply Wall Street | Illumina (ILMN) Stock Climbs On Clinical Growth Despite Margin Pressure Simply Wall Street | View source ↗ | Simply Wall Street | Jul 31, 2026 | neutral | 0 | 0.6 |
| Why Illumina (ILMN) Stock Is Down Today - Yahoo Finance | Why Illumina (ILMN) Stock Is Down Today Yahoo Finance | View source ↗ | Yahoo Finance | Jun 30, 2026 | neutral | 0 | 0.6 |
| Illumina (ILMN) Stock After 80% One-Year Rebound Is The Price Now Justified - Yahoo Finance | Illumina (ILMN) Stock After 80% One-Year Rebound Is The Price Now Justified Yahoo Finance | View source ↗ | Yahoo Finance | Jun 24, 2026 | neutral | 0 | 0.6 |
| Why Illumina (ILMN) Stock Is Trading Up Today - StockStory | Why Illumina (ILMN) Stock Is Trading Up Today StockStory | View source ↗ | StockStory | Jun 24, 2026 | neutral | 0 | 0.6 |
| ILMN Stock Jumps 98.7% in a Year: What's Powering the Surge? - TradingView | ILMN Stock Jumps 98.7% in a Year: What's Powering the Surge? TradingView | View source ↗ | TradingView | Jun 3, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.